Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sutro Biopharma Inc STRO

Healthcare Biotechnology
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed... see more

Recent & Breaking News (NDAQ:STRO)

Sutro Biopharma to Present at Two Upcoming Investor Conferences

PR Newswire April 8, 2021

Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board

PR Newswire March 22, 2021

Sutro Biopharma Reports Full Year 2020 Financial Results and Provides Business Highlights and 2021 Anticipated Milestones

PR Newswire March 18, 2021

Sutro Biopharma to Participate in the Cowen 41st Annual Healthcare Conference

PR Newswire February 23, 2021

Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer

PR Newswire January 21, 2021

Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference

PR Newswire January 5, 2021

Sutro Biopharma Announces Closing of Upsized $144.9 Million Public Offering, including Full Exercise of the Underwriters' Option to Purchase Additional Shares

PR Newswire December 11, 2020

Sutro Biopharma Announces Pricing of $126.0 Million Public Offering

PR Newswire December 8, 2020

Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common Stock

PR Newswire December 7, 2020

Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting

PR Newswire December 7, 2020

Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer

PR Newswire December 3, 2020

Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors

PR Newswire December 1, 2020

Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer

PR Newswire November 24, 2020

Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations

PR Newswire November 18, 2020

Sutro Biopharma to Participate in Four Upcoming Investor Conferences

PR Newswire November 11, 2020

Sutro Biopharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights and Developments

PR Newswire November 5, 2020

Sutro Biopharma Named Best New Drug Developer at the 7th Annual World ADC

PR Newswire September 21, 2020

Sutro Biopharma Presents Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer at the 2020 IGCS Annual Global Meeting

PR Newswire September 9, 2020

Sutro Biopharma to Present at Two Upcoming Investor Conferences

PR Newswire September 3, 2020

Sutro Biopharma Announces Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer and Presentation at the 2020 IGCS Annual Global Meeting

PR Newswire September 2, 2020